Conference
Phase II Studies of the Glycine Antagonist GV150526 in Acute Stroke
Abstract
BACKGROUND AND PURPOSE: GV150526, a selective glycine site antagonist, reduces infarct volume in rats with focal cerebral ischemia. Safety and efficacy in humans with acute stroke are being investigated. We sought to further explore the safety, pharmacokinetics, and preliminary outcome of GV150526 treatment in patients with a clinical diagnosis of acute stroke.
METHODS: Two trials were conducted in North America. The North American Glycine …
Volume
31
Pagination
pp. 358-365
Publisher
Wolters Kluwer
Publication Date
2 2000
DOI
10.1161/01.str.31.2.358
Conference proceedings
Stroke
Issue
2
ISSN
0039-2499